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Clinical Significance 
• There is wide variety of registries on atrial fibrillation with evident differences in 
design and methodology.   
• Registry data demonstrate that despite gradual improvement in anticoagulation rates 
worldwide, there are apparent regional differences and gaps in stroke prevention with 
approximately a third of atrial fibrillation patients not treated in accord with 
guidelines.   
• Remote mortality of atrial fibrillation patients is relatively high, while guideline-
adherent antithrombotic therapy significantly reduces thromboembolism and improves 
survival. 
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ABSTRACT 
Background  
Recent improvements in atrial fibrillation diagnosis and management have prompted the 
initiation of various registries, predominantly to assess adherence to new guidelines, but also 
to address the pending questions of safety and effectiveness of newly introduced management 
options in ‘real world’ clinical practice settings. In this review we appraise antithrombotic 
treatment patterns for stroke prevention in atrial fibrillation registries. 
 
Methods and Results   
We searched PubMed, Science Direct and the Cochrane databases for registries focusing on 
stroke thromboprophylaxis in atrial fibrillation. Registry data show that over the last decade, 
the proportion of patients receiving oral anticoagulation has increased (from about 67% to 
over 80%), while the proportion of those treated with aspirin only or untreated has 
diminished. Vitamin K antagonists (VKAs) are being gradually replaced by non-VKA oral 
anticoagulants (NOACs) as the more prevalent option. Regional and country differences in 
anticoagulation are evident, with its highest uptake in Europe (90.2%) and lowest in Asia 
(57.4%). Moreover, oral anticoagulation is given to approximately 50% of patients with no 
stroke risk factors, whereas over a third of high-risk subjects are not anticoagulated but often 
prescribed antiplatelet therapy alone or untreated. Guideline non-adherent 
thromboprophylaxis results in an increase in all-cause mortality and thromboembolism. 
 
Conclusions   
Registry data show that despite an increase in anticoagulation rates over the last decade, 
management gaps in stroke prevention are still evident with about third of patients not treated 
in line with the guidelines. Mortality rates of atrial fibrillation patients remain relatively high, 
mostly due to the comorbid disease. 
 
Keywords 
Atrial fibrillation; Registry; Stroke prevention; Antithrombotic treatment 
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Over the last decade our knowledge of atrial fibrillation has substantially improved, mainly 
due to better understanding of epidemiology and pathophysiology of stroke and 
thromboembolism. As a consequence, new risk factors for stroke have been identified and our 
procedure for assessment of patients at risk has changed; formerly there was a tenacious 
search for patients at high thromboembolic risk, whereas now there is an effort to identify 
those individuals who are at truly low risk of stroke and do not need any antithrombotic 
treatment, so that stroke prevention can be focused on those with ≥1 stroke risk factors 1–6. 
These changes coincided with the introduction of non-Vitamin K Antagonist oral 
anticoagulants (NOACs), which offer greater efficacy, safety and convenience compared with 
the Vitamin K Antagonists (VKAs, e.g. warfarin) 7–10.  
 
Recently, several national and worldwide registries were initiated, predominantly to assess 
whether daily clinical practice is in accord with atrial fibrillation guidelines and to collect data 
on treatment with new drugs. Design and methodology of those registries vary substantially 
and have evolved over the last decade. This review provides an overview of past and current 
atrial fibrillation registries with respect to treatment patterns for stroke prophylaxis as well as 
aims to inform clinicians on the interpretation of results and limitations that may be inherent 
in different registry designs. 
 
Methods  
 
We searched PubMed, Science Direct and Cochrane Library databases for studies that 
reported on atrial fibrillation and stroke thromboprophylaxis. Multiple queries using following 
keywords were performed on July 1, 2016: (‘atrial fibrillation’ AND ‘registry’) AND (‘stroke 
prevention’ OR ‘antithrombotic treatment’ OR ‘oral anticoagulation’).  We screened titles and 
abstracts for relevance to the topic. Articles of selected titles and abstracts were then reviewed 
for inclusion.   
 
Purpose and Design of Various Observational Studies   
 
There is considerable variety in registry design (Tables 1-3). National registries, like e.g. 
Swedish and Danish National Patient Registries, are ‘real time’ databases of the whole 
country population, where every patient is enrolled, every prescribed drug recorded, follow-
up of patients is counted in years and vital status along with cause of death can be routinely 
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verified 11–13. There are also international registries sponsored by learned societies, such as the 
EORP-AF (EURObservational Research Programme Atrial Fibrillation General Pilot 
Registry), which was initiated by the European Society of Cardiology (ESC), but its long-term 
extension to non-ESC countries continues by open collaboration, as part of the INTER-AF 
programme 14. Moreover, there are academic-led registries from one single city or defined 
region, such as Fushimi AF (Table 1) 15,16.  
 
In addition to large government sponsored databases, there are also several large, 
international, industry-sponsored registries (Table 2) such as GLORIA-AF (Global Registry 
on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) and 
GARFIELD-AF (Global Anticoagulant Registry in the FIELD) 17,18. Some registries enroll 
only outpatients, such as ORBIT-AF (Outcomes Registry for Better Informed Treatment of 
Atrial Fibrillation), J-RHYTHM or PINNACLE-AF (The American College of Cardiology 
Practice Innovation And Clinical Excellence Program), while others include only inpatients, 
e.g. Get With the Guidelines-AFIB (GWTG-AFIB) Registry 19–22. Some of the registries are 
actually linked to specific programs to improve atrial fibrillation management. For example, 
the GWTG-AFIB is a United States (US) nationwide quality improvement program, which is 
intended not only to gather data, but also to provide a wide spectrum of health care sites with 
support to improve guideline adherence, arrhythmia management, and finally treatment 
outcomes 22. There are also registries that record only baseline cross-sectional data 23,24; 
though most have follow-up analyses. Registries have varying strategies to ensure data quality 
with some implementing rigorous standards, such as on site monitoring, extensive edit checks, 
frequent manual data reviews and periodic quality review of aggregate data.  Others may not 
include such checks or make no mention of whether such standards were implemented, thus 
the measures taken to ensure data integrity should be considered when interpreting data. 
 
Euro Heart Survey - Example of an ‘Early’ Non-Industry Sponsored Registry   
 
Until 2005 there were no large scale European studies that prospectively collected data on 
atrial fibrillation epidemiology, management and outcomes. Euro Heart Survey (EHS) on 
Atrial Fibrillation was the first to verify routine clinical practice against the 2001 atrial 
fibrillation guidelines 25–27.  
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The registry enrolled 5333 in- and outpatients from 35 countries and reported oral 
anticoagulation (OAC) at 67%, with only 7% of patients not receiving any antithrombotic 
treatment. These were one of the highest OAC rates that were reported from a daily clinical 
practice in Europe 25,28,29. Nevertheless, a discordance between guidelines and clinical practice 
was noted as 49% of ineligible patients received OAC, while 33% with an indication for 
anticoagulation were not treated as such 25.  
 
Furthermore, prescription of OAC was only marginally guided by available stroke risk 
stratification schemes 26. Importantly, the well-known risk factors for stroke were often not 
the trigger for anticoagulation, whilst other factors such as atrial fibrillation pattern (less OAC 
in paroxysmal arrhythmia) or availability of an anticoagulation monitoring clinic played a 
more predominant role in antithrombotic treatment decision making 26,30. Multiplicity and 
complexity of risk stratifications schemes along with debates at that time on the importance of 
various risk factors for stroke such as hypertension or arrhythmia pattern, were some of the 
postulated reasons for guideline non-adherence 26,31,32.  
 
In 2010, two new scoring systems were proposed - CHA2DS2VASc (congestive heart disease, 
hypertension, age ≥75 years [doubled], diabetes, stroke/TIA [transient ischemic 
attack]/systemic thromboembolism [doubled], vascular disease, age ≥65 years, sex category 
[female]) to assess stroke risk and HAS-BLED (hypertension, abnormal renal/liver function, 
stroke, bleeding, labile international normalized ratio, age>65 years, drug/alcohol intake) for 
bleeding risk assessment 2,33,34. Both scales are presently recommended by European and 
American guidelines 35–37.  
 
10 Years Later – What Do We Know from Ongoing Registries Today?  
 
Non-Industry Sponsored Registries 
European Perspective 
In 2012 the ESC established the EORP-AF General Pilot Registry to systematically collect 
contemporary data on atrial fibrillation treatment by cardiologists in Europe 14. The registry 
enrolled 3119 in- and outpatients with atrial fibrillation diagnosed within the preceding year 
and shortly after first NOACs were on offer. This registry showed OAC use at 80.0% (71.6% 
VKAs and 8.4% NOACs), with 1/3 of patients receiving other antithrombotics (mostly 
aspirin) and 4.8% no antithrombotic treatment 38,39. Surprisingly, OACs were used in 56.4% 
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of patients with CHA2DS2-VASc=0, whereas only 66.7% of those with CHA2DS2-VASc=9 
were anticoagulated 38. 
 
Guideline-adherent antithrombotic therapy was low at 61%, with 17.3% of patients being 
undertreated and 21.7% overtreated 40. Importantly, antithrombotic management which was in 
line with the 2012 ESC guidelines, was associated with significantly better outcomes (all 
cause death/thromboembolic event of 9.0%), whereas the corresponding numbers for under- 
and overtreatment were 14.3% and 13.9% respectively 40.  
 
One-year outcomes of EHS and EORP-AF Pilot Registry were strikingly similar. Mortality 
rates were 5.3% vs 5.7% respectively and the cause of death was cardiovascular in 67% vs 
70%, respectively 41,42. Death rates were highest in both registries in persistent/permanent 
atrial fibrillation, but also in a first-detected arrhythmia. However, one year stroke rates were 
higher in EHS than in EORP-AF (1.8% vs 0.6% respectively) 41,42. Of note, in the EHS 
anticoagulation was discontinued in 45% of patients with no reoccurrence of arrhythmia and 
in 63% patients who were considered cured 42. This is of importance, as undertreatment 
resulted in a 2-fold increase in thromboembolic events, compared with guideline-adherent 
management 30.  
 
North American Perspective 
OAC was low in the US outpatient registry sponsored by the American College of Cardiology 
(ACC) called PINNACLE 21. This registry was a nationwide, prospective quality 
improvement program designed to capture, report and improve outpatient management in the 
pre-NOAC era. Between July 2008 and December 2009, the registry included 9113 patients 
from 20 US sites where overall OAC was only 55.1% 21. These results showed a great 
variation in OAC prescribing across different US outpatient practices as well as near-random 
pattern of anticoagulation distribution 43. In a larger analysis of 71,972 patients, subjects with 
paroxysmal atrial fibrillation were less commonly treated with OAC than those with persistent 
arrhythmia (50.4% vs. 64.3% respectively) but more frequently with antiplatelet therapy or no 
antithrombotic drugs 44. In contrast, 26.6% with CHA2DS2-VASc=0 were prescribed OAC, 
despite having no indications for such treatment 45. 
 
AF Registries Centred on Asia 
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Very low anticoagulation rates were reported from Asia, particularly China, where only 
approximately 20% of patients received OAC, while 40% were on aspirin and 40% untreated, 
resulting in an annual stroke risk of 9.28% 46–50. By contrast, OAC was associated with annual 
stroke risk reduction by >50% and the adjusted net clinical benefit favouring OAC therapy 
over antiplatelet or no therapy for all patients with CHA2DS2-VASc score ≥1 46,51–54. In Japan, 
OAC rates are better than in China, though anticoagulation control is generally suboptimal. In 
the J-RHYTHM Registry, despite a high overall OAC at 87.3%, only 53% patients met 
target INR (International Normalized Ratio) levels 20,55–57.  
 
Industry-Sponsored Registries  
Suboptimal adherence to guidelines and regional differences in treatment patterns have been 
also observed in industry-sponsored registries.  
 
GLORIA-AF is one of the largest, currently ongoing registries, that was initiated in 2011, 
and aims to enroll up to 56,000 patients from nearly 50 countries worldwide 17. It has an 
innovative inception cohort design consisting of 3 overlapping phases (Figure 1 and Tables 2-
3). The first phase of the study includes a period before NOAC introduction, the second phase 
begins immediately following approval of NOACs in a given country, and the third phase 
starts following propensity score comparisons in a region, between patient populations on 
VKA vs NOACs, to ensure baseline characteristics of those patients can be reasonably 
compared 17. Such a registry design allows collection of data where there is dynamically 
changing clinical practice and available treatment methods with a reduced study bias. It also 
allows description of the pre-NOAC era 58 and the early period immediately following first 
NOAC approval 59, and can further inform about changing prescription patterns as the 
landscape of NOAC availability changes.  It also implements a ‘new user’ design, which only 
includes incident cases of atrial fibrillation (diagnosed within the previous 3 months) to limit 
the potential for confounding factors such as disease co-morbidity 17,59.  
 
Report from phase I (between May 2011 and January 2013) of GLORIA-AF showed OAC at 
64.1% and 20.3% in Europe and China, respectively 58.  Though results of phase II (between 
November 2011 and February 2014) comprising over 10,000 patients were still showing 
regional differences in antithrombotic treatment patterns, the overall OAC uptake 
substantially increased to 80% (32.3% VKA and 47.7% NOAC) 59. The highest OAC rates 
were observed in Europe at 90.2%, followed by 78.2% in North America and 57.4% in Asia 
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59
. A considerable number of patients were still treated with antiplatelet therapy (5.7% in 
Europe, 14.1% in North America and 25.8% in Asia) or remained untreated (4.1% in Europe, 
7.6% in North America and 16.9% in Asia).  
 
GARFIELD-AF is another large scale, ongoing, international registry, initiated by the 
Thrombosis Research Institute, London 18. The registry design is to enroll patients in 5 
independent, sequential and prospective (but overlapping) cohorts and 4 of the cohorts enroll 
only subjects with newly diagnosed arrhythmia (Figure 2 and Tables 2-3) 18.  
 
Data from the first out of five registry cohorts with 10,614 patients enrolled between 2009 and 
2011 showed that 60.3% of patients received OAC (45.2% VKA alone, 4.5% NOAC), while 
25.3% were given antiplatelet therapy alone and 14.4% did not use any antithrombotic drugs 
60
. Contraindications to OAC were reported in only 7.8% of patients, yet 40.7% of eligible 
patients with a CHA2DS2-VASc score ≥2 were not given OAC, while in contrast 38.7% of 
those with a score of 0 received anticoagulation.  
 
OAC uptake in GARFIELD-AF has improved over time. It was 57.4% in 2010 and increased 
to 71.1% in 2015. At the same time, NOAC uptake increased from 4.1% to 37% 61. 
Importantly, the two-year all-cause mortality was 3.83 per 100 person-years and was far more 
frequent than the incidence of stroke or major bleeding (1.25 and 0.70 per 100 person-years, 
respectively) 62. The cause of death was cardiovascular in 40.5% of cases and congestive heart 
failure with sudden cardiac death were responsible for 10.8% and 7.5% of deaths, respectively 
62
. 
 
Comparing the Registries 
 
Direct comparison of registries is not straightforward (Tables 1-3). There are different 
inclusion criteria for atrial fibrillation and its duration. For example, in GLORIA-AF and 
GARFIELD-AF only new onset arrhythmia (<6 weeks in GARFIELD-AF and <3 months in 
GLORIA-AF) is permitted, while it is <12 months in PREFER-AF and arrhythmia detected 
by implantable pacemaker/cardioverter-defibrillator is also allowed 17,18,63.  
 
While most of the registries include only non-valvular atrial fibrillation, PREFER-AF or 
ORBIT-AF permitted also valvular arrhythmia 19,63. GLORIA-AF requires at least one stroke 
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risk factor in CHA2DS2-VASc scale, while GARFIELD-AF does not use any stroke risk 
scales, enrolling patients with at least one risk factor at the discretion of physicians. PREFER-
AF or ORBIT-AF enroll ‘all comers’, regardless of presence or absence of stroke risk factors 
17,18,63
. To omit the influence of previous anticoagulation, GLORIA-AF excluded patients with 
a history of VKA therapy ≥60 days, whereas the rest of the registries are recruiting patients 
irrespective of previous or current OAC (Table 3).  
 
Comparison of anticoagulation rates requires consideration of several factors, the most 
important of which seem to be the calendar year and time period of data collection. Indeed, 
OAC uptake is gradually, but constantly increasing worldwide and thus more recent reports 
show higher OAC rates 59,61. However, registry design, regional contribution and availability 
of approved medications are also important (Table 3) 17,59. Impact of site and setting may also 
play a role as e.g. registries from the region of Asia/Pacific may report lower OAC rates 59,60. 
The proportions of in- and outpatients, academic institutions, participating physician 
specialties, patients of different ethnicities, different health care providers, and funding of the 
registries need to be also considered 59,60,63,64. Indeed, in several registries, OAC was high 
where cardiologists were responsible for treatment 25,26,38,41,59,65. When a broader spectrum of 
care settings was analyzed, including patients treated by other specialists, then the overall 
OAC was lower 60,66.  
 
Finally, there are various atrial fibrillation guidelines issued by different organizations, which 
may differ with respect to stroke prevention recommendations 67. American guidelines for 
example permit the use of aspirin or even no antithrombotic treatment in some patients (e.g. 
with CHA2DS2-VASc=1) 36.  
 
Quo Vadis?  Has Clinical Practice Changed? 
 
Since the EHS over a decade ago (2003-2004), the overall use of OAC has increased, from 
67% in EHS to 80.5% in EORP-AF (2012-2013), 82.3% in PREFER-AF (2012-2013), 80% in 
GLORIA-AF (2011-2014), and 71.1% in GAREFIELD-AF (2010-2015) 38,39,41,59,61,65. Based 
on data from GLORIA-AF, NOACs are currently gradually replacing VKA both in Europe, 
where already more patients are prescribed NOACs, and in North America, when the usage of 
NOACs is twice as high as warfarin 59.  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
 
Possible reasons for an increase in OAC prescription over the last years may be increasing 
availability of NOACs, but also new guidelines and increased awareness of atrial fibrillation 
and stroke burden. This is also reflected by the falling number of patients being prescribed 
aspirin or those untreated 25,40. Contemporary registries also demonstrate that by performance 
improvement efforts, any treatment gaps can be identified and bridged 38,39,41,59,61,65,68. In the 
GWTG program, as a result of a tailored feedback and clinical decision support 
anticoagulation rates reached 95% 68.  
 
However, despite best efforts, guideline-adherent thromboprophylaxis is still suboptimal. 
Indeed, approximately half of truly low-risk patients are overtreated with OAC, while a third 
of high risk patients are not anticoagulated 38,39,59,65. Potential reasons are complex and 
include fear of bleeding complications, especially in certain patient populations (with low 
body weight, anemia, chronic kidney disease and the elderly), a perception that certain 
patterns of atrial fibrillation are more benign (paroxysmal or asymptomatic arrhythmia), 
subtherapeutic INR values, lack of good INR monitoring, and finally even cultural or habitual 
differences in treatment patterns 16,56,57,69–71.   
 
Contraindications (approximately 10% of patients) and refusal to accept OAC are also 
important as these are often subjective and change over time 72. These patients are generally 
older and more frail, with multiple comorbidities, but also at higher risk of stroke. In the 
ORBIT-AF registry, the most frequent reasons for warfarin forgoing were physician 
preference/choice (47.7%) and patient preference/refusal (21.1%) 60,73.  
 
Conclusions 
Though differences amongst registries on atrial fibrillation are evident, their main findings are 
similar and consistent thus giving us a very comprehensive insight into current clinical 
practice. Despite a gradual increase in anticoagulation rates worldwide, gaps in stroke 
prevention are still apparent, while guideline-adherent thromboprophylaxis improves 
outcomes 30,40. Long-term mortality of atrial fibrillation patients is relatively high, exceeding 
both ischemic and bleeding events, mainly due to comorbid disease 41,42,62.  
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Figure legend  
 
Figure 1  
Design of the GLORIA-AF Registry 17  
M – month; YR – year 
 
Figure 2 
GARFIELD Registry Design 18 
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Table 1 Non-Industry Sponsored Registries 
Registry Size 
(n) 
Start 
date 
Inclusion criteria Follow-up Design Country Comment 
Euro Heart Survey on AF 25–28,30–32 5333 2003 AF confirmed by ECG 
within 1 year before 
diagnosis, inpatients/ 
outpatients 
1 year Prospective 
observational 
35 
European  
countries 
First large prospective registry assessing AF management 
against 2001 ACC/AHA/ESC guidelines; 
AF undertreatment results in a 2-fold increase in 
thromboembolism; 
Need for simple stroke/bleeding risk scale 
ESC EORP AF Pilot 14,38,40–42 3119 2012 AF confirmed by ECG 
within 1 year before 
diagnosis, inpatients/ 
outpatients 
1 year Prospective, 
consecutive, 
observational 
9 EU 
countries 
Non-adherence to 2012 ESC AF guidelines increases 
mortality;  
Antithrombotic overtreatment of low risk patients (with 
CHA2DS2-VASc=0) and undertreatment of high risk 
patients (1/3 on antiplatelet therapy)  
PINNACLE-AF 
(National 
Cardiovascular Data 
Registry) 21,43–45 
>121000 2008 AF, outpatients ongoing National 
prospective, 
office-based, 
cardiac quality 
improvement 
registry 
US Antithrombotic overtreatment of low risk AF pts; 
Undertreatment of paroxysmal AF pts with moderate to 
high risk scores 
Get With the Guidelines-AFIB 
(National 
Cardiovascular Data 
Registry) 22,68,75,76 
>5 million 
pts 
2013 AF, 
inpatients 
ongoing Part of the 
national 
prospective, 
cardiac quality 
improvement 
programme 
US Large data registry; 
Support for healthcare providers and patients; 
Antithrombotic undertreatment of pts with AF and stroke 
Get With the Guidelines-ACTION 
Registry (National 
Cardiovascular Data 
Registry) 77 
4959 2007 Acute myocardial 
infarction and AF 
2 years National 
prospective, 
cardiac quality 
improvement 
programme 
US Triple therapy (DAPT plus warfarin) vs DAPT in AF 
patients after acute myocardial infarction increases major 
bleeding with no difference in composite myocardial 
infarction, death or stroke 
J-RHYTHM 20,55–57,78,79 7937 2009 AF, outpatients 2 years National, 
prospective, 
observational 
Japan OAC in sub-therapeutic doses; narrow INR values (1.6 and 
2.59); female gender not an independent risk factor for 
stroke; 
Fushimi 15,16,69–71,80 3304 2011 AF, inpatients/ 
outpatients 
2 years community-
based survey of 
consecutive AF 
patients 
Japan, 
Kyoto 
Kyoto region registry;  
high representation of private clinics of general 
practitioners;  
Overall OAC rate at 53.1% and therapeutic INR at 54.4% 
resulting in non-different outcomes between OAC and non-
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OAC users. 
Nationwide Danish AF cohort 11,13  1996 AF, inpatients/ 
outpatients 
ongoing National Patient 
Register; 
Consecutive AF 
patients 
Denmark Extensive data on all hospital admissions in Denmark since 
1977. Civil registration system holds information on vital 
status of all citizens 
Nationwide Swedish AF Cohort 12  2005 AF, inpatients/ 
outpatients 
ongoing National Patient 
Register; 
Retrospective, 
unselected AF 
patients 
Sweden Extensive national data for all patients since 1997 
Nationwide Taiwan AF Cohort 50,81   1999 AF, inpatients/ 
outpatients 
ongoing National Patient 
Register; 
Retrospective, 
unselected AF 
Taiwan Extensive national data for all patients since 1996 
 
 
AF = Atrial Fibrillation, ACC = American College of Cardiology, AHA = American Heart Association, DAPT = Dual Antiplatelet Therapy, ESC = European Society of 
Cardiology, EU = European Union, INR = International Normalized Ratio, OAC = Oral Anticoagulation, pts = patients, US = United States,  
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Table 2 Pharma-Industry Sponsored Registries 
Registry Size 
(n) 
Start 
date 
Inclusion criteria Follow-up Design Country Comment 
RealiseAF Survey 23,24 10,523 2009 AF confirmed by ECG within 
1 year before diagnosis 
Cross-
sectional 
observation 
only 
Cross-sectional observational  
survey; 
Participating physicians 
randomly selected from 
physician list forms 
831 sites 
in 26 
countries 
and four 
continents 
Great regional differences in OAC 
uptake; 
Overuse or underuse of antithrombotics 
in approximately 50% of pts 
GLORIA-AF 17,58,59 56,000 2011 New AF diagnosis - within 3 
months, CHA2DS2-VASc ≥1 
3 years in 
phase III 
Prospective, inception cohort 
design, 
3 phases: 
1. Pre-NOAC 
2. With NOAC 
3. Propensity comparison of pts 
on VKA vs NOAC 
5 regions, 
>1000 
sites in 50 
countries 
Strong design through increased 
comparability and minimized bias; high 
representativeness; 
27000 patients to date; 
Broad physician representation; 
More than 1/5 of patients in North 
America and 1/3 in Asia under- or not 
treated with OAC  
GARFIELD-AF 18,60–62 57,000 2009 New AF diagnosis - within 6 
weeks, at least 1 risk factor by 
physician assessment 
Minimum 2 
years, up to 
8 years 
Parallel enrollment of 5 
prospective cohorts of 
unselected, consecutive patients 
with 1 retrospective validation 
cohort; 5 overlapping phases 
 
1048 sites 
in 32 
countries 
Over 49000 pts enrolled; 
C1-4 complete 
C5 since Aug 2015 
CHA2DS2-VASc 3.2; 
Broad spectrum of care-settings; 
Overtreatment of low-risk patients and 
undertreatment of high-risk ones;  
½ of patients at moderate to high stroke 
risk not treated with OAC due to 
physician decision 
PREFER-AF 63,65,82,83 7243 2012 History of AF within the 
preceding 12 months, 
inpatients/outpatients 
1 year prospective 461 sites 
in 7 West 
and South 
Europe 
countries 
AF management against 2010 guidelines; 
valvular AF not excluded; tendency 
towards a higher use of OAC in patients 
with higher stroke risk scores;  
substantial regional differences in OAC 
uptake 
ORBIT-AF I 19,64,66,84–
86
 
10,126 2009 Incident + prevalent AF, 
outpatients  
3 years Prospective, ambulatory-based  184 US 
outpatient 
practices  
CHADS2 score 2.3; 
valvular AF not excluded; 
Includes cost and quality of life 
assessment; 
Broad spectrum of health care providers; 
higher use of OAC in patients with higher 
stroke risk scores; 
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Discrepancy in OAC prescription 
amongst different care providers 
ORBIT-AF II 87 15,000 2013 New AF diagnosis (within 6 
months) or/and initiation or  
transitioned to NOACs within 
the last 3 months 
2 years Prospective, ambulatory-based 300 US 
outpatient 
practices  
Main focus on safety and effectiveness of 
NOACs (dosing, temporary interruptions, 
perioperative and bleeding management) 
used in community practice settings 
 
AF = atrial fibrillation, OAC = oral anticoagulation, NOAC = non-vitamin K oral antagonist, pts = patients, US = United States 
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Table 3 Comparison of Registries Supported by Pharma Industry  
 
GLORIA-AF 
(Phase II, n=10871) 59 
GARFIELD 
(Cohort 1, n=10614) 60,61 
PREFER-AF 
( n=7243) 63 
ORBIT-AF I 
( n=10097) 66 
ORBIT AF II 
( n=1011) 87 
Site 
 
International including US 
 
International excluding US International excluding US US only US only 
Setting 
 
Inpatients/outpatients  
(broad spectrum of settings) 
 
Inpatients/outpatients Inpatients/outpatients Outpatients only 
Outpatients only  
(academic and private 
clinics) 
Physicians  
 
Cardiologists/neurologists/internists/ 
geriatricians/GPs; 
 92% of patients enrolled by 
cardiologists    
 
Cardiologists/neurologists/internists/ 
Geriatricians/GPs; 
59% of patients enrolled by 
cardiologists    
Cardiologists/other 
specialists; 
89% patients enrolled by 
cardiologists 
Internists, primary care 
physicians, cardiologists, and 
electrophysiologists; 
80.5% of patients enrolled by 
cardiologists/electrophysiologists 
Primary care physicians, 
neurologists, cardiologists, 
electrophysiologists 
Definition of  AF New onset AF < 3 months prior to baseline visit 
 
New onset AF < 6 weeks prior to 
baseline visit; 
≥6 months but ≤24 months for  
validation group (5000 pts) only in 
cohort 1 
New onset AF + all AF 
episodes < 12 months prior to 
baseline visit; AF diagnosed 
by an implanted pacemaker 
or defibrillator allowed 
Incident or prevalent AF 
New onset AF < 6 months 
prior to baseline visit 
 
New onset AF 100% 30% N/A 4.7% 76% 
History of 
anticoagulant therapy 
Patients excluded if with the history 
of VKA therapy > 60 days  
Patients included regardless of prior 
or current VKA use 
Patients included regardless 
of prior or current VKA use 
Patients included regardless of 
prior or current VKA use 
 
Previous VKA treatment 
allowed; 
Initiation or transition to 
NOAC < 3 months  
Stroke risk scales CHA2DS2VASc≥1 needed for inclusion 
 
≥ 1 stroke risk factor by the 
physician 
discretion;CHADS2/CHA2DS2VASc 
scales not needed for inclusion 
CHADS2/CHA2DS2VASc 
scales not needed for 
inclusion 
CHADS2/CHA2DS2VASc scales 
not needed for inclusion 
CHADS2/CHA2DS2VASc 
scales not needed for 
inclusion 
Mean CHADS2 score 1.9 1.9 N/A 2.3 2.0 
Mean CHA2DS2VASc 
score 
3.2 3.2 3.4 3.9 N/A 
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Enrollment timeframes 
with respect to NOAC 
approval dates 
Sites selected only once NOACs 
available  
 
Enrollment in time intervals 
irrespective of marketing 
authorization 
Enrollment irrespective of 
marketing authorization 
Enrollment irrespective of 
marketing authorization 
Enrollment after NOACs 
approval 
Overall OAC uptake 80% 62% 82% 76% 86% 
Overall OAC uptake 
by drug type 
32.3% VKA 
47.7% NOACs 
58% VKA 
4% NOACs 
76% VKA 
6% NOACs 
71% VKA 
5% NOACs 
22% VKA 
64% NOACs 
OAC uptake over time 
Phase I (2011-2013) 
              Europe - 64.1% 
             Asia - 20.3% 
             Middle East – 45.0% 
Phase II (2011-2014) 
             Europe - 90.2% 
             Asia - 57.4% 
             Middle East/Africa – 79.8% 
             North America – 78.2% 
             Latin America – 84.9% 
Cohort 1 (2009-11) - 57.5% 
Cohort 2 (2011-13) - 62.3% 
Cohort 3 (2013-14) - 67.5% 
Cohort 4 (2014-2015) -71%                      
Cohort 5 – ongoing enrollment 
N/A N/A 
 
 
N/A 
 
 
 
 
AF = atrial fibrillation, GP = General practitioner, NOAC = non-vitamin K oral antagonist, OAC = oral anticoagulation, US = United States, VKA = vitamin K antagonist 
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Clinical Significance 
• There is wide variety of registries on atrial fibrillation with evident differences 
in design and methodology.   
• Registry data demonstrate that despite gradual improvement in anticoagulation 
rates worldwide, there are apparent regional differences and gaps in stroke 
prevention with approximately a third of atrial fibrillation patients not treated 
in accord with guidelines.   
• Remote mortality of atrial fibrillation patients is relatively high, while 
guideline-adherent antithrombotic therapy significantly reduces 
thromboembolism and improves survival. 
 
[DO NOT TYPESET THE TEXT BELOW] 
Highlights 
• This paper reviews past and currently ongoing atrial fibrillation (AF) 
registries.  
• Main focus is on antithrombotic treatment patterns for stroke prevention. 
• Design, strengths and limitations of various AF registries are discussed. 
• Up-to-date situation on AF thromboprohylaxis worldwide is provided.  
• Gaps in AF guideline-adherent antithrombotic therapy were identified and 
described. 
 
 
